Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012138907 - SOLID FORMS OF CURCUMIN

Publication Number WO/2012/138907
Publication Date 11.10.2012
International Application No. PCT/US2012/032396
International Filing Date 05.04.2012
IPC
A61K 31/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
CPC
A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
C07C 229/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
229Compounds containing amino and carboxyl groups bound to the same carbon skeleton
02having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
04the carbon skeleton being acyclic and saturated
26having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 49/248
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
49Ketones; Ketenes; Dimeric ketenes
20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
24containing hydroxy groups
245containing six-membered aromatic rings
248having unsaturation outside the aromatic rings
C07D 235/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
26Oxygen atoms
C07D 235/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
30Nitrogen atoms not forming part of a nitro radical
Applicants
  • TRANSLATIONAL GENOMICS RESEARCH INSTITUTE [US]/[US] (AllExceptUS)
  • VAN ANDEL RESEARCH INSTITUTE [US]/[US] (AllExceptUS)
  • GATELY, Stephen T. [US]/[US] (UsOnly)
  • TRIEZENBERG, Steven J. [US]/[US] (UsOnly)
Inventors
  • GATELY, Stephen T.
  • TRIEZENBERG, Steven J.
Agents
  • CAI, Yu
Priority Data
61/471,80205.04.2011US
61/561,66708.11.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SOLID FORMS OF CURCUMIN
(FR) FORMES SOLUBLES DE CURCUMINE
Abstract
(EN)
Forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms. A co-crystal form of curcumin, the co-crystal form being curcumin-2-aminobenzimidazole. The said co-crystal form, curcumin-2-aminobenzimidazole, exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 6.2, about 9.0, about 12.3, about 14.5, about 17.3, about 18.0, about 19.0, about 20.0, about 21.2, about 24.5, about 25.05, and about 27.1. In particular, the co-crystal form, curcumin-2-aminobenzimidazole, exhibits an endothermic transition with an onset of about 118.1 degrees Centigrade as measured by differential scanning calorimetry.
(FR)
La présente invention concerne des formes de curcumine et les compositions pharmaceutiques à base de celles-ci. Les formes de curcumine de la présente invention sont la Forme III polymorphe de curcumine, le co-cristal curcumine-2-aminobenzimidazole et le co-cristal curcumine-L-lysine. L'invention concerne en outre des procédés d'inhibition des cellules cancéreuses et du HSV-1 à l'aide de ces nouvelles formes solides de curcumine.
Also published as
Latest bibliographic data on file with the International Bureau